Role of MMP-1 1G/2G promoter gene polymorphism on the development of prostate cancer in the Turkish population

Urol Int. 2007;79(4):312-5. doi: 10.1159/000109715.


Introduction: To investigate the association of 1G/2G polymorphism in matrix metalloproteinase-1 (MMP-1) promoter with susceptibility to prostate carcinoma in the Turkish population.

Materials and methods: MMP-1 promoter polymorphism was genotyped by PCR-RFLP analysis in 55 prostate cancer patients and 43 healthy controls.

Results: The frequency of 1G/2G genotypes in prostate cancer patients was similar to that of the controls (all p values were >0.05). Compared with the 1G/1G genotype, neither the 2G/2G nor a combination with the 1G/2G genotype significantly modified the risk of developing prostate cancer and metastasis status. In addition, the frequencies of genotypes were not significantly different among patients stratified by smoking status and family history of prostate cancer.

Conclusions: The 2G allele of the MMP-1 promoter polymorphism might not modify the risk of prostate cancer development and might not be used as a putative marker to predict the potential of metastasis in this cancer type, at least in the Turkish population.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alleles
  • Biopsy, Needle
  • Case-Control Studies
  • Genetic Predisposition to Disease*
  • Genotype
  • Humans
  • Male
  • Matrix Metalloproteinase 1 / genetics*
  • Middle Aged
  • Neoplasm Staging
  • Polymorphism, Restriction Fragment Length
  • Polymorphism, Single Nucleotide*
  • Prevalence
  • Probability
  • Prognosis
  • Promoter Regions, Genetic*
  • Prostatic Neoplasms / epidemiology*
  • Prostatic Neoplasms / genetics*
  • Prostatic Neoplasms / pathology
  • Reference Values
  • Turkey / epidemiology


  • Matrix Metalloproteinase 1